The suppression of safe and effective COVID-19 treatments to secure record profits for Big Pharma cronies will go down as one of the greatest crimes against humanity.
Hydroxychloroquine (HCQ), ivermectin, and similar drugs have produced astonishing results when used to treat COVID-19 patients.
But they’ve been around for decades and their patents expired years ago.
To ensure Big Pharma earned billions in revenue from their experimental COVID-19 vaccines, a vicious smear campaign hid their beneficial effects from the public.
Health bureaucrats, mainstream media, and Big Tech were all complicit.
Without this widespread censorship of HCQ and ivermectin, the experimental jabs would never receive Emergency Use Authorization (EUA).
However, could the technical legal basis of the EUA for the experimental jabs be questioned now?
A Finnish pharmaceutical firm has earned a patent on a drug that uses both HCQ and ivermectin.
It’s a nasal spray drug that is meant to reduce the risk of serious illness.
While it’s stated the drug will help in cases where vaccine coverage is low, could this warrant the removal of the EUA from the experimental COVID-19 jabs?
The FDA’s definition of Emergency Use Authorization:
An Emergency Use Authorization (EUA) is a mechanism to facilitate the availability and use of medical countermeasures, including vaccines, during public health emergencies, such as the current COVID-19 pandemic. Under an EUA, FDA may allow the use of unapproved medical products, or unapproved uses of approved medical products in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions when certain statutory criteria have been met, including that there are no adequate, approved, and available alternatives. Taking into consideration input from the FDA, manufacturers decide whether and when to submit an EUA request to FDA.
It appears we now have an approved alternative treatment for COVID-19.
But I don’t expect the FDA to care about this development.
Finnish firm earns US patent for Covid drug containing ivermectin and hydroxychloroquine
The Turku company says its nasal spray delivers low, safe doses of hydroxychloroquine, ivermectin and aprotinin. https://t.co/HXTmTJn7lY
— MacKenzie (@Smackenziekerr) June 27, 2021
Finnish firm earns US patent for Covid drug containing ivermectin and hydroxychloroquine | Yle Uutiset | https://t.co/TciJGrBZA1 @PierreKory @Covid19Critical @BIRDGroupUK @AI_Clayton https://t.co/5PP9jnPmrX
— Frontline Freedom (@FrontlineFree) August 2, 2021
Source (thank you @barakshalev )https://t.co/Izh4ePIr48
— Gal G🕯 🇮🇱 (@GalG____) August 2, 2021
Well, how about that! Remember how hydroxychloroquine and ivermectin were rubbished as treatments for Covid? Now a Finnish firm earns a US patent for a Covid drug containing ivermectin and hydroxychloroquine. | https://t.co/ML4UM934tJ https://t.co/th3LfcMINe
— Rebecca Weisser (@RebeccaWeisser) August 3, 2021
YLE had this story that has gone untouched by U.S. mainstream news:
A coronavirus drug developed by Therapeutica Borealis, a pharmaceutical firm in Turku, has been granted a patent by the United States Patent and Trademark Office (USPTO). The nasal spray contains hydroxychloroquine, among other ingredients.
Earlier in May, the company said it had received approval for a patent application, based on which it expected a final patent this month.
“The final patent is an important milestone for us on our way to the market. Our next goal is to find an established pharmaceutical industry company with an international business scale,” says Professor Kalervo Väänänen, one of the three inventors and founders of Therapeutica Borealis, in a press release on Monday. Väänänen is a cell biologist and former rector of the University of Turku.
The co-inventors of the drug and co-founders of Therapeutica Borealis are Lauri Kangas, an adjunct professor of science at the University of Turku, and Matti Rihko, a psychologist, and board chair of the Turku Chamber of Commerce and of the University of Turku. He is also a former CEO of the Raisio food corporation, known for its cholesterol-lowering Benecol products.
According to the company, the nasal spray acts on cell function in nasal mucous in three ways, impairing the ability of the virus to penetrate the body and multiply, thus reducing the risk of serious illness.
Another Finnish pharmaceutical company, Rokote Laboratories, has been developing a coronavirus vaccine in nasal spray form, but has struggled to gain financing.
“Tackling the pandemic probably requires, in addition to a vaccine, a preventive or early-acting drug. This drug also helps especially in a situation where vaccine coverage threatens to remain too low for herd immunity,” said Väänänen.
WHO warned against ivermectin use except in clinical trials
The firm said that the drug’s active ingredients – aprotinin, hydroxychloroquine and ivermectin – are well-known and widely used drugs, but in this product are used in a new, targeted manner on the upper respiratory mucous membrane.
All the drug molecules covered by the patent are approved for the treatment of other diseases, but if used systemically, for instance as pills or infusions swallowed by patients, the amounts of drugs would be high and potentially harmful.
For topical use, as in a nasal spray, the concentrations of the active ingredients throughout the body remain very low but are sufficient locally to prevent the passage and replication of the virus, making the drug safer and more effective, says Therapeutica Borealis.
Aprotinin is a protease inhibitor while ivermectin is an antiparasitic and hydroxychloroquine has been used against malaria – and has been touted as a Covid-19 treatment by Brazilian President Jair Bolsonaro and former US President Donald Trump among others.
Another question I have is the cost to prescribe this nasal spray drug.
As I reported 7 months ago, a COVID Treatment Kit was under $3 in India.
I’m curious what this pharmaceutical firm will charge for the drug.
If it’s an exorbitant price, then it’s another scam to add to COVID-19 hysteria.